ODYSSEY THERAPEUTICS INC (ODTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.76+8.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ODTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ODTX — earnings miss
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended June 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Sect…
Why it matters: Watching cash burn is key for checking financial health. High burn can worry about survival.
Worry ifNet loss increases beyond $52.8 million in subsequent quarters.
Less concerning ifNet loss goes down or stays below $52.8 million.
Why it matters: This data could confirm the effectiveness of OD-001 and impact future trials.
Supportive ifThe Phase 2a trial of OD-001 had positive data. This was shown at the United European Gastroenterology Week.
Worry ifThe Phase 2a trial presentation had negative or unclear data.
Why it matters: Starting this trial shows progress in clinical development. It can help investor confidence.
Supportive ifThe Phase 2b monotherapy trial for OD-001 will start in the second half of 2026.
Worry ifDelay or cancellation of the Phase 2b trial for OD-001.
Why it matters: Updates on cash runway will show if the company can fund its operations and trials. This affects investor confidence.
Watch forQ3 earnings report shows cash on hand is sufficient to fund operations into the second half of 2028.
Also watch forQ3 earnings report shows cash runway is shorter than expected. It needs more funding.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$258 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $521 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,841 loss on $10,000 · 18.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Filing the CTA is a key step towards starting clinical trials for OD-002.
Supportive ifSuccessful filing of a clinical trial application for OD-002 by the end of 2026.
Worry ifFailure to file the CTA for OD-002 by the end of 2026.
Why it matters: Higher cash burn may mean financial strain. This can affect future operations.
Worry ifOperating expenses rose a lot in Q3 compared to Q2.
Less concerning ifOperating expenses stay the same or drop in Q3 compared to Q2.